{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"434.6","value":"23132.1"},{"groupId":"OG001","spread":"278.1","value":"21960.0"},{"groupId":"OG002","spread":"894.4","value":"17337.8"},{"comment":"Insufficient number of participants to calculate Geometric Coefficient of Variation.","groupId":"OG003","spread":"NA","value":"51121.0"},{"groupId":"OG004","spread":"1730.0","value":"7661.6"},{"groupId":"OG005","spread":"101.4","value":"32027.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"Cmax is the maximum or peak concentration of drug reached in the plasma following a dose of the drug.\n\nQuantitative polymerase chain reaction (qPCR) was used to determine Cmax by detecting the JCAR017 transgene.\n\nBaseline is defined as the last available recorded value on or prior to the date of JCAR017 infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in the JCAR017 treated set with baseline and on-study PK measurements.","reportingStatus":"POSTED","timeFrame":"At baseline and up until 24 months post JCAR017 infusion","title":"Maximum Concentration (Cmax) of JCAR017 by qPCR","type":"SECONDARY","unitOfMeasure":"Copies/ug"}